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Abstract
First-time users of contraception are mostly young sexually active patients who may or may not be in a stable relationship who 
would want to prevent an unwanted pregnancy. Seeing these patients presents a golden opportunity to counsel patients about 
sexually transmitted diseases, sexual health and also legal aspects regarding sexual offences. Contraceptives may also be pre-
scribed for their additional benefits like cycle control and acne and are also used to assist couples to space and plan their families. 
This article presents value information on the various methods of contraception for product selection and counselling.
 This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(2):13-18
Introduction
Contraception is used to assist couples to space and plan their 
families by preventing the occurrence of an unplanned pregnancy. 
The easy availability of contraception is one of the major advances 
in health care. Not only is effective prevention against unwanted 
pregnancy now within reach of almost every woman but there are 
also several non-contraceptive benefits associated with the use of 
contraception. This will be discussed more fully below.
First-time users of contraception will include persons in stable 
relationships as well as persons engaging in sexual activity without a 
stable or ‘family’ relationship having been developed.
Contraceptive methods can be broadly classified into four categories:
Highly reliable
•   tubal ligation or vasectomy
•   depomedroxyprogesterone 
acetate injections
•   intrauterine contraceptive 
devices
Very reliable
•   combined oral or transcutaneous 
contraception
 •   deponorethisterone oenanthate 
injections
Reliable
•  progestogen-only pills
•   male or female condoms with 
spermicides
Unreliable
•   conventional methods of 
contraception
        
In all cases the objective of the practitioner must be to provide 
reliable or very reliable contraception with ease of use and with a 
limited side-effect profile.
Benefits of contraception
A huge benefit is that the prescribing physician has the opportunity to 
discuss relationships, sexuality, sexually transmitted infections (STIs) 
including HIV, as well as reliable use of a method with the potential 
user. Barrier methods help prevent the transmission of STIs. There 
are several non-contraceptive benefits of hormonal contraception 
(Table I).
Table I: Non-contraceptive benefits of oral contraceptives
1. Programmed menstruation
2. Decreased menstrual blood loss
3. Decreased menstrual symptoms
4. Decreased incidence of benign breast disease and ovarian cysts
5. Decreased incidence of anaemia and acne
6.  Some protection against trichomoniasis and upper genital tract 
infections
7.  Protection against development of ovarian and endometrial cancer
8.  Reversibility – most women will return to normal fertility 11 to 3 
months after stopping use of the pill
Options for first-time users
 The recommended options for all first-time users are the following:
• Barrier contraception
• Combined oral contraceptives (COCs)
• Combined contraceptive patch
Barrier contraception
The male condom has been available for hundreds of years and was 
originally used for prevention of the spread of STIs. The condom is 
made from latex and is a single-use item to be placed on the penis 
during erection but prior to ejaculation. The female condom is a 
cumbersome polyurethane sheath that is inserted into the vagina 
prior to intercourse and covers the cervix, vagina and part of the 
vulva. It is available but unpopular in South Africa. Male condoms 
are currently pre-packed in a foil sachet containing a spermicide 
that also acts as a lubricant. Nonoxynol-9 and nonoxynol-11 are the 
most commonly used spermicides. On their own, spermicides are 
much less effective than condoms in preventing pregnancy. Used 
with condoms their value may be regarded as added prevention of 
pregnancy if small leaks have occurred from the condom.
Condoms are recommended for couples with infrequent or 
unplanned intercourse when another reliable method such as COC 
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is not available. Persons at risk of transmission of STIs should use 
either male or female condoms, independent of whether hormonal 
contraception is utilised. Couples requiring short-term contraception, 
for example when a woman on a COC has to use an antibiotic that 
may decrease COC effectiveness, are also advised to use condoms.
Frequent use of condoms with spermicides may be associated with 
a contact dermatitis type of vulvo-vaginitis. The patient presents with 
pruritus and slight burning and sometimes a thin watery discharge. 
There are usually no other symptoms or any sign of infectious 
vaginitis. A change in contraceptive strategy is required.
Combined oral contraceptives (COCs)
COC preparations differ from one another on the basis of the 
following:
1.  Phase: monophasic (with fixed oestrogen-progestogen dosage) 
or bi/triphasic (with  varying oestrogen and progestogen 
dosages).
2.  Dosage: low-dose or high-dose pills based on the hormone 
content per pill. 
3.  Type of progestogen: norethisterone, norgestrel, levonorgestrel, 
desogestrel, gestodene, norgestimate, drospirenone and 
cyproterone. The type of progesterone plays a major contributory 
role in the side effect and complication profile. A list of 
preparations with comments on the action is offered in Table II.
When choosing the most appropriate COC preparation the first rule 
is to start with the lowest effective dosage of one of the first-choice 
preparations in order to minimise side effects. The contra-indications 
for use of COCs are listed in Table III. The COC should be used for 
1. Gonane-containing preparations Notes
Monophasic
Ovral®: ethinyl oestradiol (EE) 50 µg, norgestrel 500 µg These are highly progestogenic COC preparations but are also highly 
oestrogenic. These are not recommended for routine contraception but 
remain useful for management of abnormal uterine bleeding or for emergency 
contraception.
Nordiol®: EE 50 µg. levonorgestrel 250 µg
Norinyl-1/28®: mestranol 0.05 mg, norethisterone 1 mg.
Nordette®: EE 30 µg, levonorgestrel 150 µg. This low-oestrogen-content COC is moderately progestogenic and therefore provides good cycle control. It remains a good first-choice preparation.
Femodene ED®, Minulette®: EE 30 µg, gestodene 75 µg.
These balanced low-dose third-generation gonane preparations are good 
first-choice preparations. Gestodene is androgenically neutral, leading to very 
few androgenic side effects.
Melodene®: EE 20 µg, gestodene 75 µg.
This is a very low- dose balanced preparation. Tablets should be taken at the 
same time each day due to the low oestrogen content, otherwise inhibition of 
FSH may not be adequate.
Marvelon®: EE 30 µg, desogestrel 150 µg. This low-dose COC is oestrogenic because of the neutral androgenicity. It is a good first-choice preparation for persons needing some oestrogenicity.
Mercilon®: EE 20 µg, desogestrel 150 µg.
This is a very low-dose slightly oestrogenic pill with less than perfect cycle 
control. Tablets should be taken at the same time each day due to the low 
oestrogen content, otherwise inhibition of FSH may not be adequate.
Mirelle®, Minesse®: 15 µg EE and 60 µg gestodene.
This is an ultra-low-dose contraceptive. This is aimed at the woman with 
stable cycle control and who is very compliant. It should be taken daily at the 
same time.
Cilest®: EE 35 µg, norgestimate 250 µg. This low-dose preparation contains more EE than other preparations.
Triphasic
Triphasil®, Logynon ED®: Phase 1: 6 tablets of EE 30 µg, levonorgestrel 
50 µg. Phase 2: 5 tablets of EE 40 µg, levonorgestrel 75 µg. Phase 3: 10 
tablets of EE 30 µg, levonorgestrel 125 µg. 
These balanced triphasic COCs are good first-choice preparations. They 
provide good cycle control.
Triodene®, Tri-Minulet®: Phase 1: 6 tablets of EE 30 µg, gestodene 50 µg. 
Phase 2: 5 tablets of EE 40 µg, gestodene 70 µg. Phase 3: EE 30 µg, 
gestodene 100 µg.       
These balanced triphasics are good first-choice preparations. They provide 
good cycle control.
Trinovum®: Phase 1: 7 tablets of EE 35 µg, norethisterone 0,5 mg. Phase 2: 
7 tablets of EE 35 µg, norethisterone 0,75 mg. Phase 3: 7 tablets of EE 35 
µg, norethisterone 1 mg.
 
Tricilest®: 7 tablets of EE 35 µg, norgestimate 0,18 mg. Phase 2: 7 tablets 
of EE 35 µg, norgestimate 0,215 mg. Phase 3: 7 tablets of EE 35 µg, 
norgestimate 0,25 mg.
These COCs have a higher oestrogen content than other preparations.
Biphasic
Biphasil®: Phase 1: 11 tablets of EE 50 µg, levonorgestrel 50 µg. Phase 2: 
10 tablets of EE 50 µg, levonorgestrel 125 µg.
This oestrogen-dominant preparation is used for women needing some 
oestrogenicity.
2. Pregnane progestogen preparations
Monophasic
Diane-35®, Ginette®, Minerva® : EE 35 µg, cyproterone acetate 2 mg. These oestrogenic anti-androgenic preparations are used against acne and hirsutism.
3. Fourth-generation progesterone preparations 
Monophasic
Yasmin®: 30 µg EE, 3 mg drosperinone
Drosperinone is the most recently used progestogen in a COC preparation. It 
pharmacologically resembles naturally occurring progesterone and also has 
some of the effects of spironolactone. The benefits are that it improves acne, 
the patient does not suffer from fluid retention due to the diuretic effect and it 
decreases menstrual and pre-menstrual complaints.
Table II: Different types of COC
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three to four months before a final assessment of acceptability of 
possible side effects is made. Either a monophasic or triphasic low-
dose COC can be used as a starting prescription. 
Table III: Contra-indications for use of COC
1.  Absolute contra-indications  
• Pregnancy
• Undiagnosed vaginal bleeding
•  Patients > 35 years who smoke and have diabetes mellitus, 
hyperlipidaemia or gross obesity
•  History of ischaemic heart disease, cerebral vascular disease or 
arterial and/or venous thrombosis
• Severe untreated hypertension
• Focal migraine
• Heart valve lesions
•  Hepatitis, history of cholestatic jaundice of pregnancy or gall bladder 
disease
• Current breast or endometrial cancer
2.  Relative contra-indications
• Diabetes mellitus
• Epilepsy
• Intestinal malabsorption syndromes
• Major depression
• Chronic renal or hepatic disease
• Planned major surgery with immobilisation
• Possibly porphyria
Common side effects of COCs
Patients using COCs may experience side effects that may indicate 
progestogen excess with oestrogen deficiency or oestrogen excess 
with progestogen deficiency. This should assist in deciding what 
preparation to change to should a change be contemplated. 
Signs and symptoms of progestogen excess with oestrogen 
deficiency include the following:
• increased appetite
• acne,  irritability, mood swings or depression
• headaches during use of the placebo tablets
• vaginal dryness
• shortened menstruation or amenorrhoea
In such cases a change to a more oestrogenic preparation should be 
considered. 
Signs and symptoms of oestrogen excess and progestogen 
deficiency include the following: 
• excessive menstruation and breakthrough bleeds
• mastodynia
• headaches during use of the active pills
• a white non-infectious vaginal discharge
• corneal oedema
In such cases a change to a more progestogenic preparation should 
be considered. 
If any change of COC is contemplated the current packet should be 
completed and the new preparation started on the corresponding 
day during menstruation. The most common side effect is poor cycle 
control presenting as breakthrough bleeding. If this occurs in the first 
half of the cycle the endometrium does not proliferate adequately 
and breaks down; more oestrogen is required and a change to a 
more balanced or oestrogenic preparation may improve the situation. 
If the bleeding occurs in the last week of the cycle or if menstrual 
blood loss is heavy, the impact of the progestogen on cycle control 
is suboptimal. A change to a more balanced or progestogenic 
preparation could be considered.
Total loss of cycle control would require temporary use of a high-
dose combined preparation. This should be taken for three to four 
months and then a balanced preparation should be used. Post-pill 
amenorrhoea rarely occurs for more than two to three months. 
Reassurance is required. Persistent post-pill amenorrhoea for more 
than six months is pathological and should be investigated, as in the 
case of other patients with secondary amenorrhoea.
Complications associated with COC use
There have been reports that gestodene- and desogestrel-containing 
drugs were associated with an increased risk for thrombo-embolic 
events and stroke in young persons, in particular young women who 
suffer from thrombophilias. It is therefore important to ask the patient 
about own or familial clotting disorders prior to prescribing one of 
these preparations. A positive answer should result in screening for 
the above-mentioned disorders, and alternative contraception should 
be planned. If the women are young and healthy a preparation 
containing gestodene and desogestrel can be used. 
COC users older than 35 years who smoke and have concomitant 
heart or vascular disease have a high risk of thrombo-embolic 
disease. Drug interaction regularly occurs with COC use. The most 
common event is use of broad-spectrum antibiotics that change the 
constituency of the intestinal flora, resulting in reduced circulating 
levels of oestrogen and thus pill inefficiency. Other drug interactions 
are due to induction of hepatic microsomal enzyme action where 
the metabolism of the COC is accelerated and the preparation loses 
effectiveness. Such drugs include the following:
•  anti-epileptic drugs phenytoin, barbiturates, carbamazepine, 
ethosuximide and primidone
• rifampicin and griseofulvin
• spironolactone
• chlorpromazine and chloral hydrate
The list of contra-indications to COC use is given in Table III.
Teenagers who are sexually active
Teenagers should be motivated to use COCs as prescribed and to 
avoid irregular use. The starting preparation should be either a low-
dose (like Yasmin® and Mercilon® or Marvelon®) or an ultra-low-dose 
product (like Mirelle®).
Teenagers, like other women in possibly short-term or unstable 
relationships or those exposed to STI or HIV transmission, should 
be motivated to use ‘double’ contraception, namely COCs as well as 
condoms to minimise the risk of transmission of STIs.
The contraceptive patch
The contraceptive patch is a valuable new addition to contraception. 
Each patch contains ethinyl oestradiol 0.9 mg and gestodene 1.9 mg 
that are secreted or released from the patch on a dose-controlled 
basis daily for a week whereafter the patch must be replaced. It is 
important that the patch be placed correctly. The effectiveness, side 
effects and long-term effects mimic those of COCs. Heat, humidity 
and exercise do not impact on the pharmacokinetics of the patch 
but if the woman has a body mass of more than 90 kg effectiveness 
may be compromised. This is a popular modern choice of hormonal 
contraception. Often six active patches are used in sequence 
followed by one placebo patch. This way menstruation can be 
postponed.
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The use of injectable contraception or intrauterine devices is not 
recommended for first-time users.
Emergency postcoital contraception
This is the use of a drug or device to prevent pregnancy after 
intercourse. This may be required after accidental intercourse, 
after condom breakage and after rape. In South Africa the most 
common method is to use ethinyl oestradiol 100 µg with 250–50 µg 
of norgestrel twice within 72 hours of the episode of intercourse and 
taken 12 hours apart. Another popular method is to insert a copper-
containing intrauterine contraceptive device (IUCD) up to five days 
after the earliest estimate of ovulation but not later than seven days 
after intercourse.
Hormonal emergency contraception will prevent about 80% of 
pregnancies. This is influenced by the time of ovulation and the 
correlation with the episode of intercourse. The failure rate of the 
IUCD is less than 1%.
Counselling opportunities
The initial consultation provides a huge counselling opportunity. This 
can lay the foundation of future contraceptive attitude and use in the 
patient. Explanation of mechanisms of action, dealing with common 
side effects and attempts to maintain constant and consistent method 
use will all help decrease the later occurrence of contraceptive 
intolerance.
Much attention should be given to STIs. The first-time user has 
often had unprotected intercourse already. Confidentiality should be 
assured, especially in the case of a teenager.
The prescription of a contraceptive should always follow on a good 
discussion and never simply replace it.  
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